All In MedTech

FDA Clearance Tracker · P170032-S017

Woven EndoBridge Aneurysm Embolization (WEB) System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 23, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 23, 2024

Approved

Time to decision

31 days

Received Aug 23, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P170032-S017
Device name
Woven EndoBridge Aneurysm Embolization (WEB) System
Applicant location
Aliso Viejo, CA
Received
Aug 23, 2024
Decided
Sep 23, 2024
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P170032

Device type

Device class
Class III

Every decision under product code OPR

FDA's approval statement

As written in FDA's record.

approval of the revised protocol for the post-approval study (PAS) referenced above. The revised PAS protocol has been submitted to comply with the conditions of approval outlined in our December 31, 2018, approval order for P170032

Source documents

Other decisions for MicroVention, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.